WO2019169988A1 - Formes cristallines d'ertugliflozine et procédé de préparation associé - Google Patents

Formes cristallines d'ertugliflozine et procédé de préparation associé Download PDF

Info

Publication number
WO2019169988A1
WO2019169988A1 PCT/CN2019/074921 CN2019074921W WO2019169988A1 WO 2019169988 A1 WO2019169988 A1 WO 2019169988A1 CN 2019074921 W CN2019074921 W CN 2019074921W WO 2019169988 A1 WO2019169988 A1 WO 2019169988A1
Authority
WO
WIPO (PCT)
Prior art keywords
ray powder
powder diffraction
diffraction pattern
crystal
degrees
Prior art date
Application number
PCT/CN2019/074921
Other languages
English (en)
Chinese (zh)
Inventor
于红琴
姚加
陈勇
罗忠华
黄芳芳
Original Assignee
广东东阳光药业有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 广东东阳光药业有限公司 filed Critical 广东东阳光药业有限公司
Priority to CN201980007142.1A priority Critical patent/CN111566112B/zh
Publication of WO2019169988A1 publication Critical patent/WO2019169988A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
    • C07H9/04—Cyclic acetals

Definitions

  • relative intensity refers to the ratio of the intensity of the other peaks to the intensity of the first strong peak when the intensity of the first strong peak of a set of diffraction peaks belonging to a certain crystal form is defined as 100%.
  • single solvent means that the solubility of the sample in the single solvent is greater than 1 g/L, or greater than 2 g/L, or greater than 3 g/L, or greater than 4 g/L, or greater than 5 g/L, or greater than 6 g/L, Or greater than 7 g/L, or greater than 8 g/L, or greater than 9 g/L, or greater than 10 g/L, or greater than 15 g/L, or greater than 20 g/L, or greater than 30 g/L, or greater than 40 g/L, or greater than 50 g/L, or greater than 60 g/L, or greater than 70 g/L, or greater than 80 g/L, or greater than 100 g/L.
  • a method for preparing Form I comprises the preparation of Eglippine Form I from amorphous form Eglipex, Eglippine Form II or/and Eglippine Form III.
  • a method for preparing Form III comprising dissolving amorphous Eglipide in a single solvent to form a solution, and then adding the solution to the anti-solvent n-hexane, stirring, crystallization, separating the solid to obtain Form III;
  • the single solvent is selected from the group consisting of isopropyl acetate and dichloroethane.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention se rapporte au domaine de la chimie pharmaceutique, et concerne en particulier, des formes cristallines d'ertugliflozine et un procédé de préparation associé. Ladite forme cristalline est une forme cristalline I, une forme cristalline II ou une forme cristalline III, et les diverses formes cristallines présentent des pics caractéristiques de diffraction de rayons X sur poudre différentes. Lesdites formes cristallines ont de meilleures propriétés telles qu'une très haute solubilité dans l'eau, une biodisponibilité élevée, une haute stabilité et une non-hygroscopicité, et peuvent être utilisées pour préparer un médicament pour traiter le diabète de type 2. Les procédés de préparation des diverses formes cristallines d'ertugliflozine sont simples, faciles à utiliser, et ont des conditions modérées.
PCT/CN2019/074921 2018-03-06 2019-02-13 Formes cristallines d'ertugliflozine et procédé de préparation associé WO2019169988A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201980007142.1A CN111566112B (zh) 2018-03-06 2019-02-13 埃格列净的晶型及其制备方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810182846.X 2018-03-06
CN201810182846 2018-03-06

Publications (1)

Publication Number Publication Date
WO2019169988A1 true WO2019169988A1 (fr) 2019-09-12

Family

ID=67846408

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2019/074921 WO2019169988A1 (fr) 2018-03-06 2019-02-13 Formes cristallines d'ertugliflozine et procédé de préparation associé

Country Status (2)

Country Link
CN (1) CN111566112B (fr)
WO (1) WO2019169988A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102149717A (zh) * 2008-08-28 2011-08-10 辉瑞大药厂 二氧杂-双环[3.2.1]辛烷-2,3,4-三醇衍生物
WO2014159151A1 (fr) * 2013-03-14 2014-10-02 Msd International Gmbh Procédés de préparation d'inhibiteurs de sglt2
CN105646603A (zh) * 2016-03-01 2016-06-08 孙霖 埃格列净晶型a及制备方法
CN105646604A (zh) * 2016-03-01 2016-06-08 孙霖 埃格列净晶型b及制备方法
WO2016088081A1 (fr) * 2014-12-03 2016-06-09 Sun Pharmaceutical Industries Limited Procédés de préparation d'ertugliflozine

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102149717A (zh) * 2008-08-28 2011-08-10 辉瑞大药厂 二氧杂-双环[3.2.1]辛烷-2,3,4-三醇衍生物
WO2014159151A1 (fr) * 2013-03-14 2014-10-02 Msd International Gmbh Procédés de préparation d'inhibiteurs de sglt2
WO2016088081A1 (fr) * 2014-12-03 2016-06-09 Sun Pharmaceutical Industries Limited Procédés de préparation d'ertugliflozine
CN105646603A (zh) * 2016-03-01 2016-06-08 孙霖 埃格列净晶型a及制备方法
CN105646604A (zh) * 2016-03-01 2016-06-08 孙霖 埃格列净晶型b及制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DAI YONGZHI: "Synthesis Research of SGLT-2 Inhibitors Ertugliflozin", MASTER'S THESES OF HUMAN UNIVERSITY OF CHINESE MEDICINE, 15 July 2013 (2013-07-15) *

Also Published As

Publication number Publication date
CN111566112A (zh) 2020-08-21
CN111566112B (zh) 2022-02-15

Similar Documents

Publication Publication Date Title
JP5798101B2 (ja) ４−メチル−ｎ−［３−（４−メチル−イミダゾール−１−イル）−５−トリフルオロメチル−フェニル］−３−（４−ピリジン−３−イル−ピリミジン−２−イルアミノ）−ベンズアミドの結晶形態
US8501753B2 (en) Useful pharmaceutical salts of 7-[(3R, 4R)-3-Hydroxy-4-hydroxymethyl-pyrrolidin-1-ylmethyl]-3, 5-dihydro-pyrrolo [3, 2-D] pyrimidin-4-one
US10150770B2 (en) Crystal form of bisulfate of JAK inhibitor and preparation method therefor
JP3726291B2 (ja) 安定な結晶構造を有するベンゾオキサジン化合物およびその製造法
WO2021088616A1 (fr) Forme cristalline de sulfate d'acide d'élagolix, préparation et utilisation associées
KR102657147B1 (ko) 빌라스틴의 결정형 및 그의 제조 방법
KR20190123607A (ko) 피마살탄 트로메타민염 및 이를 포함하는 약제학적 조성물
WO2021129589A1 (fr) Nouvelle forme cristalline de kd-025 et son procédé de préparation
WO2019169988A1 (fr) Formes cristallines d'ertugliflozine et procédé de préparation associé
WO2019080865A1 (fr) Forme cristalline d'inhibiteur de l'alcynyl pyridine prolyl hydroxylase et son procédé de préparation
AU2017259388B2 (en) Amine solvate of sodium-glucose linked transporter inhibitor, and preparation method and application thereof
US10519150B2 (en) Salts of morpholine derivative, crystal forms thereof, processes for producing the same, pharmaceutical compositions including the same, and use thereof
US10301344B2 (en) L-proline complex of sodium-glucose cotransporter 2 inhibitor, monohydrate and crystal form thereof
WO2013181251A1 (fr) Sel de chlorhydrate de crizotinib sous forme cristalline
WO2021057834A1 (fr) Forme cristalline de composé ester et son procédé de préparation
CN113801189A (zh) 一种d因子阻滞剂的晶型及其制备方法
WO2012013118A1 (fr) Cristaux de sulfate de carvédilol, leur procédé de synthèse et leurs applications pharmaceutiques
WO2017028762A1 (fr) Forme cristalline d'un composé cyclique de type naphtalène
WO2024067844A1 (fr) Forme cristalline d'hydrochlorure de fexuprazan, son procédé de préparation et son utilisation
US20190322646A1 (en) Crystalline forms of ap26113, and preparation method thereof
WO2022253234A1 (fr) Formes cristallines de dérivé de glucosamine, leur procédé de préparation et leur utilisation
WO2019120250A1 (fr) Nouvelle forme cristalline d'hémitartrate de pimavansérine et procédé de préparation de la forme cristalline
CN114105867A (zh) 一种低氧诱导因子脯氨酰羟化酶抑制剂的晶型及其制备方法
WO2024002353A1 (fr) Sel pharmaceutiquement acceptable et forme cristalline de dérivé hétérocyclique ponté azoté et leur procédé de préparation
CN115385918A (zh) 一种咪达唑仑新晶型及其制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19764634

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19764634

Country of ref document: EP

Kind code of ref document: A1